Yusef A Syed1, William Stokes1, Manali Rupji2, Yuan Liu2, Onkar Khullar3, Nikhil Sebastian1, Kristin Higgins1, Jeffrey D Bradley1, Walter J Curran1, Suresh Ramalingam4, James Taylor5, Manu Sancheti3, Felix Fernandez3, Drew Moghanaki6. 1. Department of Radiation Oncology, Emory University Winship Cancer Institute, Atlanta, GA. 2. Biostatistics Shared Resource, Emory University Winship Cancer Institute, Atlanta, GA. 3. Department of Surgery, Emory University, Atlanta, GA. 4. Department of Hematology and Medical Oncology, Emory University, Atlanta, GA. 5. Department of Radiation Oncology, Thomas Jefferson University, Philadelphia, PA. 6. Department of Radiation Oncology, University of California, Los Angeles, Los Angeles, CA. Electronic address: dmoghanaki@mednet.ucla.edu.
Abstract
BACKGROUND: Patients undergoing surgery for early stage non-small cell lung cancer (NSCLC) may be at high risk for postoperative mortality. Access to stereotactic body radiation therapy (SBRT) may facilitate more appropriate patient selection for surgery. RESEARCH QUESTION: Is postoperative mortality associated with early stage NSCLC lower at facilities with higher use of SBRT? STUDY DESIGN AND METHODS: Patients with early stage NSCLC reported to the National Cancer Database between 2004 and 2015 were included. Use of SBRT was defined by each facility's SBRT experience (in years) and SBRT to surgery volume ratios. Multivariate logistic regression was used to test for the associations between SBRT use and postoperative mortality. RESULTS: The study cohort consisted of 202,542 patients who underwent surgical resection of cT1-T2N0M0 NSCLC tumors. The 90-day postoperative mortality rate declined during the study period from 4.6% to 2.6% (P < .001), the proportion of facilities that used SBRT increased from 4.6% to 77.5% (P < .001), and the proportion of patients treated with SBRT increased from 0.7% to 15.4% (P < .001). On multivariate analysis, lower 90-day postoperative mortality rates were observed at facilities with > 6 years of SBRT experience (OR, 0.84; 95% CI, 0.76-0.94; P = .003) and SBRT to surgery volume ratios of more than 17% (OR, 0.85; 95% CI, 0.79-0.92; P < .001). Ninety-day mortality also was associated with surgical volume, region, year, age, sex, and race, among other covariates. Interaction testing between these covariates showed negative results. INTERPRETATION: Patients who underwent resection for early stage NSCLC at facilities with higher SBRT use showed lower rates of postoperative mortality. These findings suggest that the availability and use of SBRT may improve the selection of patients for surgery who are predicted to be at high risk of postoperative mortality. Published by Elsevier Inc.
BACKGROUND: Patients undergoing surgery for early stage non-small cell lung cancer (NSCLC) may be at high risk for postoperative mortality. Access to stereotactic body radiation therapy (SBRT) may facilitate more appropriate patient selection for surgery. RESEARCH QUESTION: Is postoperative mortality associated with early stage NSCLC lower at facilities with higher use of SBRT? STUDY DESIGN AND METHODS: Patients with early stage NSCLC reported to the National Cancer Database between 2004 and 2015 were included. Use of SBRT was defined by each facility's SBRT experience (in years) and SBRT to surgery volume ratios. Multivariate logistic regression was used to test for the associations between SBRT use and postoperative mortality. RESULTS: The study cohort consisted of 202,542 patients who underwent surgical resection of cT1-T2N0M0 NSCLC tumors. The 90-day postoperative mortality rate declined during the study period from 4.6% to 2.6% (P < .001), the proportion of facilities that used SBRT increased from 4.6% to 77.5% (P < .001), and the proportion of patients treated with SBRT increased from 0.7% to 15.4% (P < .001). On multivariate analysis, lower 90-day postoperative mortality rates were observed at facilities with > 6 years of SBRT experience (OR, 0.84; 95% CI, 0.76-0.94; P = .003) and SBRT to surgery volume ratios of more than 17% (OR, 0.85; 95% CI, 0.79-0.92; P < .001). Ninety-day mortality also was associated with surgical volume, region, year, age, sex, and race, among other covariates. Interaction testing between these covariates showed negative results. INTERPRETATION: Patients who underwent resection for early stage NSCLC at facilities with higher SBRT use showed lower rates of postoperative mortality. These findings suggest that the availability and use of SBRT may improve the selection of patients for surgery who are predicted to be at high risk of postoperative mortality. Published by Elsevier Inc.
Authors: Robert D Timmerman; Chen Hu; Jeff M Michalski; Jeffrey C Bradley; James Galvin; David W Johnstone; Hak Choy Journal: JAMA Oncol Date: 2018-09-01 Impact factor: 31.777
Authors: Mark W Onaitis; Anthony P Furnary; Andrzej S Kosinski; Sunghee Kim; Daniel Boffa; Betty C Tong; Patricia Cowper; Jeffrey P Jacobs; Cameron D Wright; Joe B Putnam; Felix G Fernandez Journal: Ann Thorac Surg Date: 2017-11-22 Impact factor: 4.330
Authors: Gregory M M Videtic; Joe Yujiao Chang; Indrin J Chetty; Mark E Ginsburg; Larry L Kestin; Feng-Ming Spring Kong; Brian E Lally; Billy W Loo; Benjamin Movsas; Thomas E Stinchcombe; Henning Willers; Kenneth E Rosenzweig Journal: Am J Clin Oncol Date: 2014-04 Impact factor: 2.339
Authors: Hiran C Fernando; Rodney J Landreneau; Sumithra J Mandrekar; Shauna L Hillman; Francis C Nichols; Bryan Meyers; Thomas A DiPetrillo; Dwight E Heron; David R Jones; Benedict D T Daly; Sandra L Starnes; Angelina Tan; Joe B Putnam Journal: J Thorac Cardiovasc Surg Date: 2011-08-26 Impact factor: 5.209
Authors: John N Melvan; Manu S Sancheti; Theresa Gillespie; Dana C Nickleach; Yuan Liu; Kristin Higgins; Suresh Ramalingam; Joseph Lipscomb; Felix G Fernandez Journal: J Am Coll Surg Date: 2015-04-16 Impact factor: 6.113